Joshua Fitch, Senior Editor

Findings "suggest that LUS is a promising tool for estimating respiratory outcomes in the first 2 years of life," wrote the study investigators.

The company also announced that it has surpassed its interim analysis enrollment target and expects topline phase 3 data from the FORTIFY study (NCT05775848) among individuals with LGMD21/R9 in 2025.

The USPSTF is encouraging providers to promote behavioral interventions as the primary effective intervention for weight loss in children and adolescents.

The national survey revealed parents are eager to learn more about school-based mental health services.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Water safety tips from the CDC including drowning prevention, pool chemical injury prevention, and keeping swimmers safe.

Experts highlight common waterborne illnesses, preventive tips for summer.

The decision is based on statistical significance achieved in the T2NOW trial, which demonstrated reduction of A1C.

Unexpected seasonal RSV following COVID-19 highlighted the need for ongoing research to better understand transmission and ongoing impact from the pandemic.

The primary outcome was an elevated HbA1c level greater than or equal to 5.7% (prediabetes or undiagnosed presumed T2D).

pJIA can lead to an increased risk of permanent joint damage as well as delayed growth and development.

Overall, the findings of the study support the clinical utility of combining trio-WES sequencing with CNV-seq in the etiologic diagnosis and management of early-childhood GDD.

Once-daily, steroid-free, topical roflumilast cream 0.15% has a PDUFA date of July 7, 2024.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The 2-drug, fixed-dose combination tablet contains darunavir, an HIV-1 protease inhibitor, and cobicistat, a CYP3A inhibitor that serves as a PK enhancer or “booster.”

Over the winter, the omicron JN.1 lineages overtook XBB strains as dominant.

Though some drowning prevention strategies seem common or routine, data demonstrate drowning deaths among children have risen in recent years, which should prompt conversations with families on refreshers and new prevention initiatives.

Additionally, a new weight-based oral solution, RINVOQ LQ, is now available as an option for the pediatric populations.

Management of ICEP with monoclonal antibodies against IL-5 and IgE (omalizumab) could be promising according to study authors, though extent of evidence is lacking.

Mesoblast Limited's chief executive announced a BLA resubmission for remestemcel-L is expected to be filed with the FDA this quarter.

The maximum daily dose has increased from 80 mg to 100 mg.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The disorders can impact the academic and social functioning of college students and have been associated with long-term health issues.

Prior to the federal agency's decision, children aged 5 years and older could only receive belimumab through an intravenous (IV) formulation.

The therapy was previously granted accelerated approval for the thyroid cancer indications in adults and pediatric patients aged 12 years and older.

Analysis demonstrated a significant correlation between elevated levels of serum circulating magnesium and serum vitamin D with increased risk of childhood asthma. 

The once daily extended-release oral suspension with nighttime dosing is approved to treat ADHD as a monotherapy or as an adjunctive therapy to approved CNS stimulant medications.

Peanut consumption starting in infancy resulted in lasting tolerance into adolescence.

Findings indicate that chronically high stress markers could have a role in the development of EF impairments in early adolescents with cCHD.

Wendy Ripple, MD, provides suggestions for sunscreens in the pediatric population.